Therapeutic Response

PD-L1 >= 1%, Wild type ALK, Wild type EGFR, and Wild type ROS1 status confers therapeutic sensitivity to Cemiplimab in combination with Cisplatin and Paclitaxel in patients with Non-Small Cell Lung Cancer.

Statements

Source and description